X4 Pharmaceuticals, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $-20.2M | $-20.3M | $22.0K | $1.5M |
| Jun 2022 | $-18.5M | $-18.5M | $38.0K | $1.5M |
| Sep 2022 | $-19.3M | $-19.3M | $9.0K | $1.1M |
| Dec 2022 | $-19.1M | $-19.1M | $34.0K | $1.1M |
| Mar 2023 | $-26.5M | $-26.5M | $9.0K | $1.6M |
| Jun 2023 | $-47.9M | $-47.9M | $8.0K | $2.1M |
| Sep 2023 | $-68.8M | $-68.8M | $8.0K | $2.4M |
| Dec 2023 | $46.7M | $46.7M | $35.0K | $2.5M |
| Mar 2024 | $-33.6M | $-33.7M | $59.0K | $1.7M |
| Jun 2024 | $-63.9M | $-64.0M | $134.0K | $2.4M |
| Sep 2024 | $-409.0K | $-501.0K | $92.0K | $1.8M |
| Dec 2024 | $-33.0M | $-33.0M | $41.0K | $2.2M |
| Mar 2025 | $-12.4M | $-12.4M | $0 | $519.0K |
| Jun 2025 | $-29.9M | $-29.9M | $0 | $748.0K |
| Sep 2025 | $-27.8M | $-27.8M | $0 | $760.0K |
| Dec 2025 | $-15.5M | $-15.5M | $0 | $2.3M |
| Mar 2026 | $-19.6M | $-19.6M | — | $2.4M |
| Jun 2026 | $-20.8M | $-20.8M | — | $3.1M |